Clinical trial
A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib (Iressa) In Patients With Metastatic Renal Cell Carcinoma
NCT00113529 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib (Iressa) In Patients With Metastatic Renal Cell Carcinoma
- Lead sponsor
- Pfizer
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 31, 2004
- Completion date
- October 31, 2008
- Enrollment
- 42 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.